Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Investing Activities: 2010-2025

Historic Cash from Investing Activities for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $17.0 million.

  • Iovance Biotherapeutics' Cash from Investing Activities rose 134.86% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.4 million, marking a year-over-year increase of 136.49%. This contributed to the annual value of -$96.4 million for FY2024, which is 37.90% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Cash from Investing Activities stood at $17.0 million for Q3 2025, which was up 22.90% from $13.8 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Cash from Investing Activities ranged from a high of $153.4 million in Q1 2023 and a low of -$156.8 million during Q2 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Cash from Investing Activities value was $13.8 million (recorded in 2025), while the average stood at -$18.6 million.
  • In the last 5 years, Iovance Biotherapeutics' Cash from Investing Activities crashed by 172.69% in 2024 and then spiked by 134.86% in 2025.
  • Iovance Biotherapeutics' Cash from Investing Activities (Quarterly) stood at -$72.8 million in 2023, then soared by 132.50% to $23.7 million in 2024, then skyrocketed by 134.86% to $17.0 million in 2025.
  • Its Cash from Investing Activities was $17.0 million in Q3 2025, compared to $13.8 million in Q2 2025 and $15.9 million in Q1 2025.